

Consolidated Financial Results for the Second Quarter of FY2018

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

| | FY2017 Q2 Apr. 2017-Sep. 2017 | | FY2018 Q2 Apr. 2018-Sep. 2018 | | YoY |
|--|----------------------------------|--------|----------------------------------|--------|--------|
| | Millions of Yen | Ratio | Millions of Yen | Ratio | |
| Net Sales | 25,054 | 100.0% | 23,477 | 100.0% | 93.7% |
| Cost of Sales | 15,231 | 60.8% | 14,026 | 59.7% | 92.1% |
| Gross Profit | 9,822 | 39.2% | 9,450 | 40.3% | 96.2% |
| Selling, General and Administrative Expenses | 7,949 | 31.7% | 8,486 | 36.1% | 106.8% |
| Operating Income | 1,872 | 7.5% | 960 | 4.1% | 51.3% |
| Profit Attributable to Owners of Parent | 1,643 | 6.6% | 743 | 3.2% | 45.2% |

Forecast of Consolidated Financial Results for the FY2018

| | FY2017 Actual Apr. 2017-Mar. 2018 | | FY2018 Forecast Apr. 2018-Mar. 2019 | |
|--|--------------------------------------|--------|--|--------|
| | Millions of Yen | Ratio | Millions of Yen | Ratio |
| Net Sales | 48,994 | 100.0% | 49,000 | 100.0% |
| Operating Income | 2,824 | 5.8% | 1,000 | 2.0% |
| Profit Attributable to Owners of Parent | 2,388 | 4.9% | 1,000 | 2.0% |

Sales of Main Products

(Billions of yen)

| Therapeutic Category | Products | FY2017 Q2 Actual | FY2018 Q2 Actual | FY2018 Forecast |
|---------------------------------------|--------------|---------------------|---------------------|--------------------|
| Antihypertensive agent | CANDESARTAN* | 6.84 | 6.08 | 11.73 |
| Thyroid hormone | THYRADIN | 2.63 | 3.01 | 5.52 |
| Hyperlipidemic agent | LIPDIL | 2.27 | 1.12 | 3.38 |
| LH-RH derivative | LEUPRORELIN | 2.07 | 2.08 | 4.54 |
| Prostate cancer therapeutic agent | BICALUTAMIDE | 0.85 | 0.62 | 1.17 |
| Antihypertensive agent | AMLODIPINE | 0.84 | 0.70 | 1.37 |
| Emergency contraceptive | NORLEVO | 0.62 | 0.66 | 1.26 |
| Antithyroid agent | MERCAZOLE | 0.57 | 0.60 | 1.15 |
| Poorly absorbable antimicrobial agent | RIFXIMA | 0.33 | 1.18 | 2.94 |

*Including CANDESARTAN formulation's sales